Drugs / Artemisinin

Trials 3 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT01391403 Sep 2008 → Apr 2011 schizophrenia Beijing HuiLongGuan Hospital Completed No outcome recorded
Phase 42 trials
Phase 4 NCT05004753 Sep 2020 → Feb 2021 COVID-19 Mateon Therapeutics Completed No outcome recorded
Phase 4 NCT01930331 Jan → Jul 2014 Plasmodium falciparum malaria Ifakara Health Institute Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04801017 Background Apr → Aug 2021 COVID-19 Oncotelic Inc. Unknown No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as artemisinin “Subject's compliance with the study treatment regimen of Artemisinin one (1) capsule a day for five (5) days, will be assessed during treatment period.” NCT05004753
3

NCT01930331

NCT01391403

NCT04801017

Known as Artemisinina ChEMBL registry synonym — accepted as the source's own label CHEMBL269671
Known as Artemisinine ChEMBL registry synonym — accepted as the source's own label CHEMBL269671
Known as Artemisininum ChEMBL registry synonym — accepted as the source's own label CHEMBL269671
Known as GNF-PF-5341 ChEMBL registry synonym — accepted as the source's own label CHEMBL269671
Known as Huanghuahaosu ChEMBL registry synonym — accepted as the source's own label CHEMBL269671
Known as NSC-369397 ChEMBL registry synonym — accepted as the source's own label CHEMBL269671
Known as Qing hau sau ChEMBL registry synonym — accepted as the source's own label CHEMBL269671
Modality Small molecule CHEMBL269671
Route Oral “500 mg per day for 5 days by oralNCT04801017